The Britain-based RECOVERY research programme investigating COVID-19 treatments said their findings could have a significant effect on hospital survival rates during the pandemic.
Of the patients that received the drug, 596 died within 28 days. This compared to 394 of patients who died in the control group. Data showed that treating patients requiring oxygen and suffering from significant inflammation with tocilizumab and dexamethasone reduced mortality by around one third. "There was very strong evidence that by giving them tocilizumab, we could increase the chance of somebody being discharged alive, within the first month," said Landray.Anthony Gordon, Professor of Anaesthesia and Critical Care and NIHR Research Professor at Imperial College London, welcomed the results."We know approximately 4,000 critically ill patients have already been treated with tocilizumab in the UK.
Despite dozens of trials using a host of existing medicines, until Thursday the only drug that had showed significant efficacy in treating COVID-19 was dexamethasone.
RheumatoidDisease It's for RHEUMATOID arthritis. It an autoimmune disease.
So does Ivermectin and Vitamin D and HCQ+Zn
Please add to your story that this study IS NOT YET PEER-REVIEWED
Countries where the citizens have high levels of Vitamin D in their blood have significantly lower levels of Covid19 infection, symptoms, hospitalization & deaths! Canada's C19 death rate is 186 times China's C19 death rate!
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.